641.50GBp+0.86%Mkt Cap: 44.01M GBpP/E: —Last update: 2026-05-13
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 ther…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B-62.34
P/S—
EV/EBITDA-6.62
EV/Revenue—
EPS (TTM)-1.71
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-2.50%
FCF Margin—
Operating CF-3.45M GBp
CapEx (TTM)3.92K GBp
Net Debt/EBITDA-0.40
Net Debt1.98M GBp
Technical
SMA 50885.53 (-27.6%)
SMA 200814.83 (-21.3%)
Beta1.54
S&P 52W Chg24.23%
Avg Vol (30d)27.96K
Avg Vol (10d)23.54K
Technical Indicators
RSI (14)30.2
MACD-75.8811
MACD Signal-70.8172
MACD Hist.-5.0639
BB Upper942.83 GBp
BB Middle758.23 GBp
BB Lower573.62 GBp
BB Width48.69%
ATR (14)85.32 GBp
Vol Ratio (20d)1.04x
52W Range
124.0031% of range1800.00
52W High1800.00 GBp
52W Low124.00 GBp
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-816.50%
ROA-233.73%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity1.68
Current Ratio0.43
Quick Ratio0.43
Book Value/Sh-0.1090 GBp
Cash/Share0.0490 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:400
Split DateDec 13, 2024
Ownership
Shares Out.6.43M
Float3.62M
Insiders31.15%
Institutions0.63%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap44.01M GBp
Enterprise Value33.01M GBp
Revenue (TTM)—
Gross Profit-929.89K GBp
Net Income (TTM)-9.76M GBp
Revenue/Share—
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees16
Last Price641.50 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—